Background Dermatologic toxicity represents a substantial portion of all immune-related
Introduction
Immunotherapies utilizing monoclonal antibodies against programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) have demonstrated efficacy in the treatment of many solid and hematologic malignancies. PD-1 and PD-L1 inhibitors such as pembrolizumab (PD-1), nivolumab (PD-1), durvalumab (PD-L1), and atezolizumab (PD-L1) work as checkpoint inhibitors by blocking the PD-1/PD-L1 pathway. This induces an antitumor response by releasing negative inhibitory control of the immune system, which reverses T-cell suppression. 1 Despite their clinical benefit against many cancers, immunomodulatory antibodies nonspecifically activate the immune system, which can result in a number of irAEs. 2 Although usually mild, anti-PD-1/anti-PD-L1 therapy-induced skin toxicity has a reported incidence of 30-40%. 3, 4 The most common cutaneous complications of PD-1/PD-L1 inhibitors are pruritus, maculopapular eruptions, and vitiligo. 2, 5 In recent years, checkpoint inhibitors have also been associated with the induction of autoimmune blistering disorders, such as BP. The pathogenesis of immunotherapy-associated BP has yet to be elucidated; however, it is likely related to unintended consequences of B-and T-cell activity in the setting of immune stimulation. 5 Clinically, BP is often characterized by pruritus, an urticarial eruption, subepidermal vesicles/bullae, and in rare instances, erosive mucosal lesions. In some cases, BP may present with a nonbullous, prodromal phase characterized predominantly by pruritus with or without eczematous, papular, or urticarial lesions. 6 BP is diagnosed via skin biopsy with hematoxylin and eosin in combination with direct immunofluorescence (DIF) and/or serum indirect immunofluorescence (IIF).
At present, there is no standard approach to the diagnosis of immunotherapy-related BP, and therapy is largely anecdotal in this population. The role and timing of proper evaluation of patients with new onset pruritus actively being treated with checkpoint inhibitors must be investigated. Early diagnosis of 
Materials and methods
A comprehensive review of the English-language medical literature was performed using PubMed, Ovid, and Embase databases. Search strategy identified articles with the terms "bullous pemphigoid," "bullous," "PD-1 inhibitor," "PD-L1 inhibitor," "immune checkpoint inhibitors," "pembrolizumab,"
"nivolumab," "durvalumab," "atezolizumab," and combinations thereof. Search involved all fields including title, abstract, keywords, and full text. Papers published from the start of time through July 2017 and from all origins were considered.
Fourteen publications were selected independently by two reviewers and deemed relevant to the present publication. The articles selected were published between the years of 2015 and 2017.
Results
Among Three of 21 patients experienced prolonged courses of BP with intermittent blister recurrence occurring 3 to 12 months following cessation of checkpoint inhibitor. 8, 15 Of 19 patients whose outcomes are known, cancer progression or patient death shortly after BP diagnosis and checkpoint inhibitor discontinuation was reported in seven cases. 7, 10, 11, 16, 17 Six of 21 patients developed BP with oral mucosal involvement -two of these patients experienced progression of their cancer, while the rest either achieved complete remission or maintained stable disease.
7,8,10,13
Pembrolizumab Ten of 21 BP cases were associated with pembrolizumab (Table 1 ). The median time to cutaneous toxicity was 18 weeks (range = 4-84 weeks), and the median time to bullae formation was 28 weeks (mean = 39 weeks; range = 16-84 weeks). Six of the 10 patients developed pruritus with nonspecific cutaneous lesions prior to the development of bullae. Of these six patients, median time to pruritus was 13.5 weeks (mean = 19 weeks; range = 4-45 weeks), and median time to bullae was 28 weeks (mean = 37 weeks; range = 22-78 weeks).
The highest dose of pembrolizumab administered was 10 mg/kg every 2-3 weeks. Three patients were given this dose, and two of three patients experienced pruritis and nonspecific cutaneous toxicity prior to the development of bullae. 7, 16 Dose reduction was attempted in one patient; however, pembrolizumab was ultimately discontinued following progression of malignancy and worsening dermatologic toxicity. 7 The second patient continued with pembrolizumab therapy after development of BP at cycle 26; however, they only required one additional infusion (cycle 27) before completion of their immunotherapy regimen. This patient was effectively treated with high-dose topical steroids. 16 Clinical presentation of BP in all three patients was similar and characterized by widespread skin involvement with erythematous papules/plaques and scattered bullae on the trunk and extremities. Two of three patients at this dose had BP with mucosal involvement. 7 Five patients were treated with pembrolizumab 2 mg/kg every 3 weeks. Median time to cutaneous toxicity was 18 weeks (range = 4-51 weeks), and median time to bullae formation was 24 weeks (range = 16-51 weeks). [9] [10] [11] 15, 18 Three of five patients presented with pruritus prior to the development of bullae with a median time to pruritus of 18 weeks (range = 4-31 weeks). 9, 11, 15 Clinically, BP findings ranged from few bullae on the thighs to multiple bullae with urticarial papules and Two patients received unspecified doses of pembrolizumab.
One patient improved with unreported doses of oral prednisone and topical steroids and was able to continue with pembrolizumab for 3 more months at which time immunotherapy was discontinued due to near complete response of his melanoma. 19 The other patient improved with pembrolizumab cessation, oral prednisone, and topical betamethasone dipropionate. 20 Nivolumab Nine of 21 BP cases were associated with nivolumab (Table 2) . develop new BP lesions for 10 months after drug discontinuation. 8 The other patient received 16 more doses of nivolumab 
Durvalumab
In one case of BP associated with durvalumab of unspecified dosing, time to cutaneous toxicity was 18 weeks, and time to BP diagnosis was 44 weeks (Table 3) . 8 Her BP partially improved with durvalumab cessation and topical steroids; however, BP was intermittently ongoing at least 1 year post discontinuation of therapy. 8 
Atezolizumab
In one case of BP associated with atezolizumab (1.2 g every 3 weeks), time to pruritus was 36 weeks, and bullae formed at 55 weeks (Table 3) . 12 This patient's BP improved after atezolizumab cessation and treatment with oral prednisone and doxycycline. The patient was maintained on low-dose prednisone for several months, and both his BP and cancer remained in complete remission. It is presently unclear which patients may be at risk for immunotherapy-induced BP. Previous studies have identified overexpression of specific HLA subtypes in patients with BP. 22 In particular, the major histocompatibility complex class-II allele, HLA-DQB 1*03:01, has been implicated as a predisposing factor in the development of BP. 23 Though this association has not been explicitly studied in patients with immunotherapy-induced BP, HLA typing in this population may reveal other markers of enhanced genetic susceptibility. Should such an association be established, prolonged monitoring for BP may be warranted in some patients treated with PD-1/PD-L1 inhibitors. Furthermore, this may aid in early initiation of systemic steroids or other interventions which may prevent progression or complications of BP, which can potentially prevent interruptions in cancer therapy.
A major limitation of this study is publication bias and thus, immunotherapy-induced BP may be more common than the literature suggests. In addition, varying levels of detail reported between cases made comparison between patients difficult in some instances. Information regarding treatment dosing/duration, methods of BP diagnosis, and findings in follow-up were limiting factors in analysis. Improved understanding of the mechanism by which immunotherapy may induce delayed BP is necessary, and further investigation is warranted.
